1. Chandraker A.. Diagnostic techniques in the work-up of renal allograft dysfunction—an update.
Curr Opin Nephrol Hypertens 8:1999;723–728.
2. Kasiske B.L., Gaston R.S., Gourishankar S., Halloran P.F., Matas A.J., Jeffery J., Rush D.. Long-term deterioration of kidney allograft function.
Am J Transplant 5:2005;1405–1414.
3. Sayegh M.H., Carpenter C.B.. Transplantation 50 years later—progress, challenges, and promises.
N Engl J Med 351:2004;2761–2766.
4. Terasaki P.I., Kreisler M., Mickey R.M.. Presensitization and kidney transplant failures.
Postgrad Med J 47:1971;89–100.
5. Patel R., Terasaki P.I.. Significance of the positive crossmatch test in kidney transplantation.
N Engl J Med 280:1969;735–739.
6. Pei R., Lee J.H., Shih N.J., Chen M., Terasaki P.I.. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities.
Transplantation 75:2003;43–49.
7. Li X., Ishida H., Yamaguchi Y., Tanabe K.. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Transpl Int 21:2008;1145–1152.
8. Sis B., Mengel M., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., Solez K., Baldwin W.M. 3rd, Bracamonte E.R., Broecker V., Cosio F., Demetris A.J., Drachenberg C., Einecke G., Gloor J., Glotz D., Kraus E., Legendre C., Liapis H., Mannon R.B., Nankivell B.J., Nickeleit V., Papadimitriou J.C., Randhawa P., Regele H., Renaudin K., Rodriguez E.R., Seron D., Seshan S., Suthanthiran M., Wasowska B.A., Zachary A., Zeevi A.. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups.
Am J Transplant 10:2010;464–471.
9. Cecka J.M.. Current methodologies for detecting sensitization to HLA antigens.
Curr Opin Organ Transplant 16:2011;398–403.
10. Mulley W.R., Kanellis J.. Understanding crossmatch testing in organ transplantation: a case-based guide for the general nephrologist.
Nephrology (Carlton) 16:2011;125–133.
11. Patel A.M., Pancoska C., Mulgaonkar S., Weng F.L.. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches.
Am J Transplant 7:2007;2371–2377.
12. Montgomery R.A., Lonze B.E., King K.E., Kraus E.S., Kucirka L.M., Locke J.E., Warren D.S., Simpkins C.E., Dagher N.N., Singer A.L., Zachary A.A., Segev D.L.. Desensitization in HLA-incompatible kidney recipients and survival.
N Engl J Med 365:2011;318–326.
13. Marfo K., Lu A., Ling M., Akalin E.. Desensitization protocols and their outcome.
Clin J Am Soc Nephrol 6:2011;922–936.
14. Ntokou I.S., Iniotaki A.G., Kontou E.N., Darema M.N., Apostolaki M.D., Kostakis A.G., Boletis J.N.. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
Transpl Int 24:2011;1084–1093.
15. Terasaki P.I., Ozawa M., Castro R.. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.
Am J Transplant 7:2007;408–415.
16. Ishida H., Hirai T., Kohei N., Yamaguchi Y., Tanabe K.. Significance of qualitative and quantitative evaluations of anti-HLA antibodies in kidney transplantation.
Transpl Int 24:2011;150–157.
17. Weimar W., Rischen-Vos J., de Kuiper P., Gregoor P.J., JN I.J., van Besouw N.M., Baan C.C., van der Mast B.J.. Tapering immunosuppression in recipients of living donor kidney transplants.
Nephrol Dial Transplant 19(Suppl 4):2004;iv61–iv63.
18. van Besouw N.M., van der Mast B.J., de Kuiper P., Smak Gregoor P.J., Vaessen L.M., IJzermans J.N., van Gelder T., Weimar W.. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced.
Transplantation 70:2000;136–143.
19. Reinsmoen N.L.. Cellular methods used to evaluate the immune response in transplantation.
Tissue antigens 59:2002;241–250.
20. Gebauer B.S., Hricik D.E., Atallah A., Bryan K., Riley J., Tary-Lehmann M., Greenspan N.S., Dejelo C., Boehm B.O., Hering B.J., Heeger P.S.. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool.
Am J Transplant 2:2002;857–866.
21. Babel N., Reinke P., Volk H.D.. Lymphocyte markers and prediction of long-term renal allograft acceptance.
Curr Opin Nephrol Hypertens 18:2009;489–494.
22. Nather B.J., Nickel P., Bold G., Presber F., Schonemann C., Pratschke J., Volk H.D., Reinke P.. Modified ELISPOT technique—highly significant inverse correlation of post-Tx donor-reactive IFN gamma-producing cell frequencies with 6 and 12 months graft function in kidney transplant recipients.
Transpl Immunol 16:2006;232–237.
23. Nickel P., Presber F., Bold G., Biti D., Schonemann C., Tullius S.G., Volk H.D., Reinke P.. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients.
Transplantation 78:2004;1640–1646.
24. Najafian N., Salama A.D., Fedoseyeva E.V., Benichou G., Sayegh M.H.. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients.
J Am Soc Nephrol 13:2002;252–259.
25. Kim S.H., Oh E.J., Kim M.J., Park Y.J., Han K., Yang H.J., Kim J.Y., Choi B.S., Yang C.W., Kim Y.S., Bang B.K.. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients.
Transplant Proc 39:2007;3057–3060.
26. Reinsmoen N.L., Cornett K.M., Kloehn R., Burnette A.D., McHugh L., Flewellen B.K., Matas A., Savik K.. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection.
Transplantation 85:2008;462–470.
27. Bestard O., Nickel P., Cruzado J.M., Schoenemann C., Boenisch O., Sefrin A., Grinyo J.M., Volk H.D., Reinke P.. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients.
J Am Soc Nephrol 19:2008;1419–1429.
28. Cherkassky L., Lanning M., Lalli P.N., Czerr J., Siegel H., Danziger-Isakov L., Srinivas T., Valujskikh A., Shoskes D.A., Baldwin W., Fairchild R.L., Poggio E.D.. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.
Am J Transplant 11:2011;1388–1396.
29. Poggio E.D., Augustine J.J., Clemente M., Danzig J.M., Volokh N., Zand M.S., Hricik D.E., Heeger P.S.. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection.
Transplantation 83:2007;847–852.
30. Heidt S., Roelen D.L., de Vaal Y.J., Kester M.G., Eijsink C., Thomas S., van Besouw N.M., Volk H.D., Weimar W., Claas F.H., Mulder A.. A novel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals.
Am J Transplant 12:2012;1469–1478.
31. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., Burdick J., Elmagd K.A., Zeevi A., López-Cepero M., Daller J.A., Gritsch H.A., Reed E.F., Jonsson J., Hawkins D., Britz J.A.. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay.
Transplantation 82:2006;663–668.
32. Perez-Flores I., Sanchez-Fructuoso A., Santiago J.L., Fernandez-Arquero M., Calvo N., de la Concha E.G., Barrientos A.. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients.
Transplant Proc 41:2009;2106–2108.
33. Huskey J., Gralla J., Wiseman A.C.. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection.
Clin J Am Soc Nephrol 6:2011;423–429.
34. Serban G., Whittaker V., Fan J., Liu Z., Manga K., Khan M., Kontogianni K., Padmanabhan A., Cohen D., Suciu-Foca N., Ratner L., Colovai A.I.. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy.
Hum Immunol 70:2009;882–890.
35. Ling X., Xiong J., Liang W., Schroder P.M., Wu L., Ju W., Kong Y., Shang Y., Guo Z., He X.. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis.
Transplantation 93:2012;737–743.
36. Zhou H., Wu Z., Ma L., Wu W., Yang S., Wang Q., Yuan X., Wu L., Lin X., Tan J.. Assessing immunologic function through CD4 T-lymphocyte ahenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation.
Transplant Proc 43:2011;2574–2578.
37. Kennedy M.K., Willis C.R., Armitage R.J.. Deciphering CD30 ligand biology and its role in humoral immunity.
Immunology 118:2006;143–152.
38. Altermann W., Schlaf G., Rothhoff A., Seliger B.. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
Nephrol Dial Transplant 22:2007;2795–2799.
39. Cinti P., Pretagostini R., Arpino A., Tamburro M.L., Mengasini S., Lattanzi R., De Simone P., Berloco P., Molajoni E.R.. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations.
Transplantation 79:2005;1154–1156.
40. Süsal C., Pelzl S., Opelz G.. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.
Transplantation 76:2003;1231–1232.
41. Sengul S., Keven K., Gormez U., Kutlay S., Erturk S., Erbay B.. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation.
Transplantation 81:2006;1216–1219.
42. Barbano G., Cappa F., Prigione I., Pistoia V., Cohen A., Chiesa S., Gusmano R., Perfumo F.. Plasma levels of soluble CD30 are increased in children with chronic renal failure and with primary growth deficiency and decrease during treatment with recombination human growth hormone.
Nephrol Dial Transplant 16:2001;1807–1813.
43. Pelzl S., Opelz G., Daniel V., Wiesel M., Süsal C.. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection.
Transplantation 75:2003;421–423.
44. Weimer R., Süsal C., Yildiz S., Staak A., Pelzl S., Renner F., Dietrich H., Daniel V., Kamali-Ernst S., Ernst W., Padberg W., Opelz G.. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens.
Am J Transplant 6:2006;1865–1874.
45. Hamer R., Roche L., Smillie D., Harmer A., Mitchell D., Molostvov G., Lam F.T., Kashi H., Tan L.C., Imray C., Fletcher S., Briggs D., Lowe D., Zehnder D., Higgins R.. Soluble CD30 and Cd27 levels in patients undergoing HLA antibody-incompatible renal transplantation.
Transpl Immunol 23:2010;161–165.
46. Langan L.L., D'Orsogna L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., Christiansen F.T.. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study.
Clin Transpl 2006;219–225.
47. Yang J.L., Hao H.J., Zhang B., Liu Y.X., Chen S., Na Y.Q.. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes.
Transplant Proc 40:2008;3381–3383.
48. Domingues E.M., Matuck T., Graciano M.L., Souza E., Rioja S., Falci M.C.. Monteiro de Carvalho DB, Porto LC: Panel reactive HLA antibodies, soluble CD30 levels, and acute rejection six months following renal transplant.
Clin Transplant 24:2010;821–829.
49. Wang D., Wu G.J., Wu W.Z., Yang S.L., Chen J.H., Wang H., Lin W.H., Wang Q.H., Zeng Z.X., Tan J.M.. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection.
Transpl Immunol 17:2007;278–282.
50. Slavcev A., Honsova E., Lodererova A., Pavlova Y., Sajdlova H., Vitko S., Skibova J., Striz I., Viklicky O.. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft.
TransplImmunol 18:2007;22–27.
51. Platt R.E., Wu K.S., Poole K., Newstead C.G., Clark B.. Soluble CD30 as a prognostic factor for outcome following renal transplantation.
J Clin Pathol 62:2009;662–663.
52. Lopez-Hoyos M., San Segundo D., Benito M.J., Fernandez-Fresnedo G., Ruiz J.C., Rodrigo E., Gomez-Alamillo C., Benito A., Arias M.. Association between serum soluble CD30 and serum creatinine before and after renal transplantation.
Transplant Proc 40:2008;2903–2905.
53. Nakao K., Nagake Y., Okamoto A., Ichikawa H., Yamamura M., Makino H.. Serum levels of soluble CD26 and CD30 in patients on hemodialysis.
Nephron 91:2002;215–221.
54. Chrul S., Polakowska E.. Age-dependent changes of serum soluble CD30 concentration in children.
Pediatr Transplant 15:2011;515–518.
55. Dieterlen M.T., Eberhardt K., Tarnok A., Bittner H.B., Barten M.J.. Flow cytometry-based pharmacodynamic monitoring after organ transplantation.
Methods Cell Biol 103:2011;267–284.
56. Pearl J.P., Parris J., Hale D.A., Hoffmann S.C., Bernstein W.B., McCoy K.L., Swanson S.J., Mannon R.B., Roederer M., Kirk A.D.. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.
Am J Transplant 5:2005;465–474.
57. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A.. Fazekas de St Groth B: Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.
J Exp Med 203:2006;1693–1700.
58. Heidt S., San Segundo D., Shankar S., Mittal S., Muthusamy A.S., Friend P.J., Fuggle S.V., Wood K.J.. Peripheral blood sampling for the detection of allograft rejection: biomarker identification and validation.
Transplantation 92:2011;1–9.
59. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A.. FOXP3+ regulatory T cells in the human immune system.
Nat Rev Immunol 10:2010;490–500.
60. Wood K.J., Sakaguchi S.. Regulatory T cells in transplantation tolerance.
Nat Rev Immunol 3:2003;199–210.
61. Vallotton L., Hadaya K., Venetz J.P., Buehler L.H., Ciuffreda D., Nseir G., Codarri L., Villard J., Pantaleo G., Pascual M.. Monitoring of CD4+CD25highIL-7Ralphahigh activated T cells in kidney transplant recipients.
Clin J Am Soc Nephrol 6:2011;2025–2033.
62. Braudeau C., Racape M., Giral M., Louis S., Moreau A., Berthelot L., Heslan M., Ashton-Chess J., Soulillou J.P., Brouard S.. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome.
Transpl Int 20:2007;845–855.
63. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M.. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.
Blood 113:2009;5125–5133.
64. Chen M.L., Yan B.S., Bando Y., Kuchroo V.K., Weiner H.L.. Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis.
J Immunol 180:2008;7327–7337.
65. San Segundo D., Fabrega E.. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
Transplant Proc 39:2007;2290–2292.
66. Segundo D.S., Ruiz J.C., Izquierdo M., Fernandez-Fresnedo G., Gomez-Alamillo C., Merino R., Benito M.J., Cacho E., Rodrigo E., Palomar R., Lopez-Hoyos M., Arias M.. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
Transplantation 82:2006;550–557.
67. Demirkiran A., Kok A., Kwekkeboom J., Metselaar H.J., Tilanus H.W., van der Laan L.J.. Decrease of CD4+CD25+ T cells in peripheral blood after liver transplantation: association with immunosuppression.
Transplant Proc 37:2005;1194–1196.
68. Hendrikx T.K., Velthuis J.H., Klepper M., van Gurp E., Geel A., Schoordijk W., Baan C.C., Weimar W.. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.
Transpl Int 22:2009;884–891.
69. Vincenti F., Blancho G., Durrbach A., Friend P., Grinyo J., Halloran P.F., Klempnauer J., Lang P., Larsen C.P., Muhlbacher F., Nashan B., Soulillou J.P., Vanrenterghem Y., Wekerle T., Agarwal M., Gujrathi S., Shen J., Shi R., Townsend R., Charpentier B.. Five-year safety and efficacy of belatacept in renal transplantation.
J Am Soc Nephrol 21:2010;1587–1596.
70. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., Bluestone J.A.. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
Immunity 12:2000;431–440.
71. Bluestone J.A., Liu W., Yabu J.M., Laszik Z.G., Putnam A., Belingheri M., Gross D.M., Townsend R.M., Vincenti F.. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation.
Am J Transplant 8:2008;2086–2096.
72. Ashoor I.F., Najafian N.. Rejection and regulation: a tight balance.
Curr Opin Organ Transplant 17:2012;1–7.
73. Pallier A., Hillion S., Danger R., Giral M., Racape M., Degauque N., Dugast E., Ashton-Chess J., Pettre S., Lozano J.J., Bataille R., Devys A., Cesbron-Gautier A., Braudeau C., Larrose C., Soulillou J.P., Brouard S.. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype.
Kidney Int 78:2010;503–513.
74. Sagoo P., Perucha E., Sawitzki B., Tomiuk S., Stephens D.A., Miqueu P., Chapman S., Craciun L., Sergeant R., Brouard S., Rovis F., Jimenez E., Ballow A., Giral M., Rebollo-Mesa I., Le Moine A., Braudeau C., Hilton R., Gerstmayer B., Bourcier K., Sharif A., Krajewska M., Lord G.M., Roberts I., Goldman M., Wood K.J., Newell K., Seyfert-Margolis V., Warrens A.N., Janssen U., Volk H.D., Soulillou J.P., Hernandez-Fuentes M.P., Lechler R.I.. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.
J Clin Invest 120:2010;1848–1861.
75. Newell K.A., Asare A., Kirk A.D., Gisler T.D., Bourcier K., Suthanthiran M., Burlingham W.J., Marks W.H., Sanz I., Lechler R.I., Hernandez-Fuentes M.P., Turka L.A., Seyfert-Margolis V.L.. Identification of a B cell signature associated with renal transplant tolerance in humans.
J Clin Invest 120:2010;1836–1847.
76. Anglicheau D., Suthanthiran M.. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns.
Transplantation 86:2008;192–199.
77. Simon T., Opelz G., Wiesel M., Ott R.C., Süsal C.. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients.
Am J Transplant 3:2003;1121–1127.
78. Vasconcellos L.M., Schachter A.D., Zheng X.X., Vasconcellos L.H., Shapiro M., Harmon W.E., Strom T.B.. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts.
Transplantation 66:1998;562–566.
79. Zarkhin V., Sarwal M.M.. Microarrays: monitoring for transplant tolerance and mechanistic insights.
Clin Lab Med 28:2008 385–410. vi.
80. Veale J.L., Liang L.W., Zhang Q., Gjertson D.W., Du Z., Bloomquist E.W., Jia J., Qian L., Wilkinson A.H., Danovitch G.M., Pham P.T., Rosenthal J.T., Lassman C.R., Braun J., Reed E.F., Gritsch H.A.. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts.
Hum Immunol 67:2006;777–786.
81. Li B., Hartono C., Ding R., Sharma V.K., Ramaswamy R., Qian B., Serur D., Mouradian J., Schwartz J.E., Suthanthiran M.. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine.
N Engl J Med 344:2001;947–954.
82. Netto M.V., Fonseca B.A., Dantas M.. Saber LT, Castro MC, Ferraz AS: Granzyme B, FAS-ligand and perforin expression during acute cellular rejection episodes after kidney transplantation: comparison between blood and renal aspirates.
Transplant Proc 34:2002;476–478.
83. Shin G.T., Kim S.J., Lee T.S., Oh C.K., Kim H.. Gene expression of perforin by peripheral blood lymphocytes as a marker of acute rejection.
Nephron Clin Pract 100:2005;c63–c70.
84. Graziotto R., Del Prete D., Rigotti P., Anglani F., Baldan N., Furian L., Valente M., Antonello A., Marchini F., D'Angelo A., Gambaro G.. Perforin, Granzyme B, and fas ligand for molecular diagnosis of acute renal-allograft rejection: analyses on serial biopsies suggest methodological issues.
Transplantation 81:2006;1125–1132.
85. Iwase H., Kobayashi T., Kodera Y., Miwa Y., Kuzuya T., Iwasaki K., Haneda M., Katayama A., Takeda A., Morozumi K., Watarai Y., Uchida K., Nakao A.. Clinical significance of regulatory T-cell-related gene expression in peripheral blood after renal transplantation.
Transplantation 91:2011;191–198.
86. Alvarez C.M., Opelz G., Garcia L.F., Süsal C.. Expression of regulatory T-cell-related molecule genes and clinical outcome in kidney transplant recipients.
Transplantation 87:2009;857–863.
87. Moraes-Vieira P.M., Takenaka M.C., Silva H.M., Monteiro S.M., Agena F., Lemos F., Saitovitch D., Kalil J., Coelho V.. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation.
Clin Immunol 142:2012;117–126.
88. Aquino-Dias E.C., Joelsons G., da Silva D.M., Berdichevski R.H., Ribeiro A.R., Veronese F.J., Goncalves L.F., Manfro R.C.. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function.
Kidney Int 73:2008;877–884.
89. Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J.B., Hartono C., Li B., Sharma V.K., Seshan S.V., Kapur S., Hancock W.W., Schwartz J.E., Suthanthiran M., Messenger R.N.A.. for FOXP3 in the urine of renal-allograft recipients.
N Engl J Med 353:2005;2342–2351.
90. Sawitzki B., Schlickeiser S., Reinke P., Volk H.D.. Monitoring tolerance and rejection in organ transplant recipients.
Biomarkers 16(Suppl 1):2011;S42–S50.
91. Sawitzki B., Bushell A., Steger U., Jones N., Risch K., Siepert A., Lehmann M., Schmitt-Knosalla I., Vogt K., Gebuhr I., Wood K., Volk H.D.. Identification of gene markers for the prediction of allograft rejection or permanent acceptance.
Am J Transplant 7:2007;1091–1102.
92. Schaub S., Rush D., Wilkins J., Gibson I.W., Weiler T., Sangster K., Nicolle L., Karpinski M., Jeffery J., Nickerson P.. Proteomic-based detection of urine proteins associated with acute renal allograft rejection.
J Am Soc Nephrol 15:2004;219–227.
93. Schaub S., Wilkins J.A., Antonovici M., Krokhin O., Weiler T., Rush D., Nickerson P.. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts.
Am J Transplant 5:2005;729–738.
94. Schaub S., Mayr M., Honger G., Bestland J., Steiger J., Regeniter A., Mihatsch M.J., Wilkins J.A., Rush D., Nickerson P.. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology.
Transplantation 84:2007;104–112.
95. Schaub S., Wilkins J.A., Nickerson P.. Proteomics and renal transplantation: searching for novel biomarkers and therapeutic targets.
Contrib Nephrol 160:2008;65–75.
96. Schaub S., Nickerson P., Rush D., Mayr M., Hess C., Golian M., Stefura W., Hayglass K.. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis.
Am J Transplant 9:2009;1347–1353.
97. O'Riordan E., Orlova T.N., Mei J.J., Butt K., Chander P.M., Rahman S., Mya M., Hu R., Momin J., Eng E.W., Hampel D.J., Hartman B., Kretzler M., Delaney V., Goligorsky M.S.. Bioinformatic analysis of the urine proteome of acute allograft rejection.
J Am Soc Nephrol 15:2004;3240–3248.
98. O'Riordan E., Orlova T.N., Podust V.N., Chander P.N., Yanagi S., Nakazato M., Hu R., Butt K., Delaney V., Goligorsky M.S.. Characterization of urinary peptide biomarkers of acute rejection in renal allografts.
Am J Transplant 7:2007;930–940.
100. Ann. Surg.
101. Clarke W.. Proteomic research in renal transplantation.
Ther Drug Monit 28:2006;19–22.
102. Wittke S., Haubitz M., Walden M., Rohde F., Schwarz A., Mengel M., Mischak H., Haller H., Gwinner W.. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients.
Am J Transplant 5:2005;2479–2488.
103. Naesens M., Sarwal M.M.. Harnessing the diversity of the human T-cell repertoire: a monitoring tool for transplantation tolerance?
Eur J Immunol 40:2010;2986–2989.
104. Miqueu P., Degauque N., Guillet M., Giral M., Ruiz C., Pallier A., Braudeau C., Roussey-Kesler G., Ashton-Chess J., Dore J.C., Thervet E., Legendre C., Hernandez-Fuentes M.P., Warrens A.N., Goldman M., Volk H.D., Janssen U., Wood K.J., Lechler R.I., Bertrand D., Sebille V., Soulillou J.P., Brouard S.. Analysis of the peripheral T-cell repertoire in kidney transplant patients.
Eur J Immunol 40:2010;3280–3290.